Skip to main content
Top
Published in: Drugs 8/2011

01-05-2011 | R&D Insight Profile

Ipilimumab

First Global Approval

Authors: Fiona Cameron, Glenn Whiteside, Caroline Perry

Published in: Drugs | Issue 8/2011

Login to get access

Abstract

Ipilimumab (Yervoy®) is an anti-cytotoxic T-lymphocyte antigen (CTLA)-4 monoclonal antibody that has been approved in the US for the first- or second-line treatment of patients with malignant melanoma. In the EU, it is awaiting approval as second-line therapy for melanoma. Ipilimumab blocks the effects of the negative T-cell regulator CTLA-4, which may in turn augment T-cell responses to tumour cells. Preclinical studies have indicated that antibody blocking of CTLA-4 can lead to potent immune responses. Ipilimumab is also in development as first- and second-line therapy for prostate cancer where it has progressed to phase III clinical trials worldwide, and it is in phase II development for non-small cell lung cancer. Ipilimumab was originated by the University of California, Berkeley, in the US and subsequently licensed to Medarex, which was later acquired by Bristol-Myers Squibb. This article summarizes the milestones in the development of intravenous ipilimumab leading to this first approval.
Literature
1.
go back to reference Hoos A, Chasalow SD, Parker SM, Siegel J, et al. Ipilimumab 10 mg/kg induction dosing promotes T-cell activation in patients with advanced melanoma. 33rd Congress of the European Society for Medical Oncology: abstr. 785P, 12 Sep 2008. Available from URL: http://annonc.oxfordjournals.org. Bristol-Myers Squibb, Wallingford, USA Hoos A, Chasalow SD, Parker SM, Siegel J, et al. Ipilimumab 10 mg/kg induction dosing promotes T-cell activation in patients with advanced melanoma. 33rd Congress of the European Society for Medical Oncology: abstr. 785P, 12 Sep 2008. Available from URL: http://​annonc.​oxfordjournals.​org.​ Bristol-Myers Squibb, Wallingford, USA
3.
go back to reference Bristol-Myers Squibb Company. FDA Approves YERVOY(Tm) (ipilimumab) for the Treatment of Patients with Newly Diagnosed or Previously-Treated Unresectable or Metastatic Melanoma, the Deadliest Form of Skin Cancer. Media Release: 26 Mar 2011. Available from URL: http://www.bms.com Bristol-Myers Squibb Company. FDA Approves YERVOY(Tm) (ipilimumab) for the Treatment of Patients with Newly Diagnosed or Previously-Treated Unresectable or Metastatic Melanoma, the Deadliest Form of Skin Cancer. Media Release: 26 Mar 2011. Available from URL: http://​www.​bms.​com
4.
go back to reference Bristol-Myers Squibb Company. Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data and Double-Digit EPS Growth. Media Release: 22 Jul 2010. Available from URL: http://www.bms.com Bristol-Myers Squibb Company. Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data and Double-Digit EPS Growth. Media Release: 22 Jul 2010. Available from URL: http://​www.​bms.​com
5.
go back to reference Bristol-Myers Squibb Company. Controlled Phase 2 Study of Ipilimumab Shows Clinical Activity in Advanced Non-Small Cell Lung Cancer. Media Release: 22 May 2010. Available from URL: http://www.bms.com Bristol-Myers Squibb Company. Controlled Phase 2 Study of Ipilimumab Shows Clinical Activity in Advanced Non-Small Cell Lung Cancer. Media Release: 22 May 2010. Available from URL: http://​www.​bms.​com
6.
go back to reference Medarex Inc. Ipilimumab (MDX-010) Shows Encouraging Data in Phase I and Phase II Clinical Trials for Hormone Refractory Prostate Cancer Patients. Media Release: 5 Jun 2006. Available from URL: http://www.medarex.com Medarex Inc. Ipilimumab (MDX-010) Shows Encouraging Data in Phase I and Phase II Clinical Trials for Hormone Refractory Prostate Cancer Patients. Media Release: 5 Jun 2006. Available from URL: http://​www.​medarex.​com
7.
go back to reference Cell Genesys Inc. Cell Genesys Reports Data on an Association Between Immune Response and Anti-Tumor Activity in Patients Receiving GVAX Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010). Media Release: 16 Apr 2008. Available from URL: http://www.cellgenesys.com Cell Genesys Inc. Cell Genesys Reports Data on an Association Between Immune Response and Anti-Tumor Activity in Patients Receiving GVAX Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010). Media Release: 16 Apr 2008. Available from URL: http://​www.​cellgenesys.​com
8.
go back to reference Cell Genesys Inc, Medarex Inc. Cell Genesys and Medarex Report Follow-Up Data From a Phase 1 Combination Therapy Trial With GVAX Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010) Antibody. Media Release: 4 Jun 2007. Available from URL: http://www.cellgenesys.com Cell Genesys Inc, Medarex Inc. Cell Genesys and Medarex Report Follow-Up Data From a Phase 1 Combination Therapy Trial With GVAX Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010) Antibody. Media Release: 4 Jun 2007. Available from URL: http://​www.​cellgenesys.​com
9.
go back to reference Kavanagh B, Rini B, Weinberg V, et al. CTLA-4 blockade-based immunotherapy for hormone-refractory prostate cancer. 2006 Prostate Cancer Symposium: abstr. 255, 24 Feb 2006 Kavanagh B, Rini B, Weinberg V, et al. CTLA-4 blockade-based immunotherapy for hormone-refractory prostate cancer. 2006 Prostate Cancer Symposium: abstr. 255, 24 Feb 2006
10.
go back to reference Dai D, Wu C, Parker SM, et al. Model-based evaluation of ipilimumab dosage regimen in patients with advanced melanoma. 44th Annual Meeting of the American Society of Clinical Oncology: abstr. 9073, 30 May 2008. Available from URL: http://www.asco.org Dai D, Wu C, Parker SM, et al. Model-based evaluation of ipilimumab dosage regimen in patients with advanced melanoma. 44th Annual Meeting of the American Society of Clinical Oncology: abstr. 9073, 30 May 2008. Available from URL: http://​www.​asco.​org
11.
go back to reference Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncology 2010; 11: 155–64. Memorial Sloan-Kettering Cancer Center, New York, New York, USAPubMedCrossRef Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncology 2010; 11: 155–64. Memorial Sloan-Kettering Cancer Center, New York, New York, USAPubMedCrossRef
12.
go back to reference Small EJ, Tchekmedyian NS, Rini BI, et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 13: 1810–1815, No. 6, 15 Mar 2007. University of California-San Francisco, San Francisco, California, USACrossRef Small EJ, Tchekmedyian NS, Rini BI, et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 13: 1810–1815, No. 6, 15 Mar 2007. University of California-San Francisco, San Francisco, California, USACrossRef
13.
go back to reference Weber JS, Hamid O, Wolchok J, et al. Assessment of Pharmacokinetic Interaction Between Ipilimumab and Chemotherapy in a Randomized Study. 35th Congress of the European Society for Medical Oncology: abstr. 1329P, 8 Oct 2010. Available from URL: http://www.esmo.org. H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA Weber JS, Hamid O, Wolchok J, et al. Assessment of Pharmacokinetic Interaction Between Ipilimumab and Chemotherapy in a Randomized Study. 35th Congress of the European Society for Medical Oncology: abstr. 1329P, 8 Oct 2010. Available from URL: http://​www.​esmo.​org. H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
14.
go back to reference The Angeles Clinic and Research Institute. The Angeles Clinic and Research Institute Announces Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previously-Treated Patients with Metastatic Melanoma. Media Release: 6 Jun 2010. Available from URL: http://www.theangelesclinic.org The Angeles Clinic and Research Institute. The Angeles Clinic and Research Institute Announces Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previously-Treated Patients with Metastatic Melanoma. Media Release: 6 Jun 2010. Available from URL: http://​www.​theangelesclinic​.​org
15.
go back to reference Bristol-Myers Squibb Company. Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previously-Treated Patients with Metastatic Melanoma. Media Release: 6 Jun 2010. Available from URL: http://www.bms.com Bristol-Myers Squibb Company. Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previously-Treated Patients with Metastatic Melanoma. Media Release: 6 Jun 2010. Available from URL: http://​www.​bms.​com
16.
go back to reference Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–23PubMedCrossRef Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–23PubMedCrossRef
17.
go back to reference Bristol-Myers Squibb Company, Medarex Inc. Results from Three Phase 2 Studies Reported a Two-Year Survival Rate Ranging from 30 to 42 Percent in Metastatic Melanoma Patients Treated with Ipilimumab (10 mg/kg). Media Release: 1 Jun 2009. Available from URL: http://www.bms.com Bristol-Myers Squibb Company, Medarex Inc. Results from Three Phase 2 Studies Reported a Two-Year Survival Rate Ranging from 30 to 42 Percent in Metastatic Melanoma Patients Treated with Ipilimumab (10 mg/kg). Media Release: 1 Jun 2009. Available from URL: http://​www.​bms.​com
18.
go back to reference Bristol-Myers Squibb Company, Medarex Inc. Updated Survival Data from Three Phase 2 Ipilimumab Studies Showed Almost Half of Previously Treated Metastatic Melanoma Patients Alive Beyond One Year. Media Release: 16 Sep 2008. Available from URL: http://www.bms.com Bristol-Myers Squibb Company, Medarex Inc. Updated Survival Data from Three Phase 2 Ipilimumab Studies Showed Almost Half of Previously Treated Metastatic Melanoma Patients Alive Beyond One Year. Media Release: 16 Sep 2008. Available from URL: http://​www.​bms.​com
19.
go back to reference Bristol-Myers Squibb Company, Medarex Inc. New Ipilimumab Survival Data in Patients with Metastatic Melanoma Presented at American Society of Clinical Oncology Annual Meeting. Media Release: 2 Jun 2008. Available from URL: http://www.medarex.com Bristol-Myers Squibb Company, Medarex Inc. New Ipilimumab Survival Data in Patients with Metastatic Melanoma Presented at American Society of Clinical Oncology Annual Meeting. Media Release: 2 Jun 2008. Available from URL: http://​www.​medarex.​com
20.
go back to reference Medarex Inc, Bristol-Myers Squibb. Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma. Media Release: 10 Dec 2007. Available from URL: http://www.medarex.com Medarex Inc, Bristol-Myers Squibb. Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma. Media Release: 10 Dec 2007. Available from URL: http://​www.​medarex.​com
21.
go back to reference O’Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Annals of Oncology: 10 Feb 2010. Available from URL: http://dx.doi.org/10.1093/annonc/mdq013. Angeles Clinic and Research Institute, Santa Monica, California, USA O’Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Annals of Oncology: 10 Feb 2010. Available from URL: http://​dx.​doi.​org/​10.​1093/​annonc/​mdq013.​ Angeles Clinic and Research Institute, Santa Monica, California, USA
22.
go back to reference Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab adminstered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clinical Cancer Research 2009; 15: 5591–98PubMedCrossRef Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab adminstered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clinical Cancer Research 2009; 15: 5591–98PubMedCrossRef
23.
go back to reference Thompson JA, The Global Ipilimumab Melanoma Study Group. Effect of prior treatment status on the efficacy and safety of ipilimumab monotherapy in treatment-naive and previously treated patients with advanced melanoma. 44th Annual Meeting of the American Society of Clinical Oncology: abstr. 9055, 30 May 2008. Available from URL: http://www.asco.org. Bristol-Myers-Squibb Pharmaceutical Research Institute, Princeton, New Jersey, USA Thompson JA, The Global Ipilimumab Melanoma Study Group. Effect of prior treatment status on the efficacy and safety of ipilimumab monotherapy in treatment-naive and previously treated patients with advanced melanoma. 44th Annual Meeting of the American Society of Clinical Oncology: abstr. 9055, 30 May 2008. Available from URL: http://​www.​asco.​org. Bristol-Myers-Squibb Pharmaceutical Research Institute, Princeton, New Jersey, USA
24.
go back to reference Weber JS, The Global Ipilimumab Melanoma Study Group. Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma. 44th Annual Meeting of the American Society of Clinical Oncology: (plus oral presentation) abstr. 9010, 30 May 2008. Available from URL: http://www.asco.org Weber JS, The Global Ipilimumab Melanoma Study Group. Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma. 44th Annual Meeting of the American Society of Clinical Oncology: (plus oral presentation) abstr. 9010, 30 May 2008. Available from URL: http://​www.​asco.​org
25.
go back to reference Medarex Inc. Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma. Media Release: 1 Jun 2008. Available from URL: http://www.medarex.com Medarex Inc. Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma. Media Release: 1 Jun 2008. Available from URL: http://​www.​medarex.​com
26.
go back to reference Medarex Inc. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab. Media Release: 5 Jun 2007. Available from URL: http://www.bms.com Medarex Inc. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab. Media Release: 5 Jun 2007. Available from URL: http://​www.​bms.​com
27.
go back to reference Weber JS, O’Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. Journal of Clinical Oncology 2008; 26(36): 5950–56PubMedCrossRef Weber JS, O’Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. Journal of Clinical Oncology 2008; 26(36): 5950–56PubMedCrossRef
28.
go back to reference Medarex Inc. Anti-Cancer Responses in Metastatic Melanoma Patients Linked to Immune Activation by MDX-010 Published in the ‘Proceedings of the National Academy of Sciences’ (PNAS). Media Release: 25 Jun 2003. Available from URL: http://www.medarex.com Medarex Inc. Anti-Cancer Responses in Metastatic Melanoma Patients Linked to Immune Activation by MDX-010 Published in the ‘Proceedings of the National Academy of Sciences’ (PNAS). Media Release: 25 Jun 2003. Available from URL: http://​www.​medarex.​com
29.
go back to reference Medarex Inc, Bristol-Myers Squibb Company. Phase II Clinical Study of MDX-010/MDX-1379 Combination Shows Durable Responses in Patients with Metastatic Melanoma. Media Release: 20 Apr 2005. Available from URL: http://www.medarex.com. Bristol-Myers Squibb Company, New York, New York, USA Medarex Inc, Bristol-Myers Squibb Company. Phase II Clinical Study of MDX-010/MDX-1379 Combination Shows Durable Responses in Patients with Metastatic Melanoma. Media Release: 20 Apr 2005. Available from URL: http://​www.​medarex.​com. Bristol-Myers Squibb Company, New York, New York, USA
30.
go back to reference Medarex Inc. Interim Ipilimumab (MDX-010) Phase II Trial Results Indicate Well-Tolerated, Extended Dosing with Preliminary Evidence that Immune Activation May Reduce Relapse in the Adjuvant Setting in Melanoma. Media Release: 5 Jun 2006. Available from URL: http://www.medarex.com Medarex Inc. Interim Ipilimumab (MDX-010) Phase II Trial Results Indicate Well-Tolerated, Extended Dosing with Preliminary Evidence that Immune Activation May Reduce Relapse in the Adjuvant Setting in Melanoma. Media Release: 5 Jun 2006. Available from URL: http://​www.​medarex.​com
31.
go back to reference Medarex Inc, Bristol-Myers Squibb. Medarex and Bristol-Myers Squibb Announce Complete and Partial Responses Observed in Phase I/II Clinical Study of MDX-010 in Combination with Il-2. Media Release: 7 Mar 2005. Available from URL: http://www.medarex.com. Medarex Inc, Princeton, New Jersey, USA Medarex Inc, Bristol-Myers Squibb. Medarex and Bristol-Myers Squibb Announce Complete and Partial Responses Observed in Phase I/II Clinical Study of MDX-010 in Combination with Il-2. Media Release: 7 Mar 2005. Available from URL: http://​www.​medarex.​com. Medarex Inc, Princeton, New Jersey, USA
32.
go back to reference Urba WJ, Weber JS, O’Day SJ, et al. Long-term survival of patients with advanced melanoma who received ipilimumab administered at 10 mg/kg every 3 weeks for 4 doses (induction dosing). 44th Annual Meeting of the American Society of Clinical Oncology: abstr. 3018, 30 May 2008. Available from URL: http://www.asco.org. Medarex, Inc., Princeton, New Jersey, USA Urba WJ, Weber JS, O’Day SJ, et al. Long-term survival of patients with advanced melanoma who received ipilimumab administered at 10 mg/kg every 3 weeks for 4 doses (induction dosing). 44th Annual Meeting of the American Society of Clinical Oncology: abstr. 3018, 30 May 2008. Available from URL: http://​www.​asco.​org. Medarex, Inc., Princeton, New Jersey, USA
33.
go back to reference Medarex Inc. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting. Media Release: 15 Apr 2008. Available from URL: http://www.medarex.com Medarex Inc. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting. Media Release: 15 Apr 2008. Available from URL: http://​www.​medarex.​com
34.
go back to reference Fong L, Kwek S, Kavanagh B, et al. CTLA-4 blockade for hormone refractory prostate cancer: dose-dependent induction of CD8+ T cell activation and clinical responses. 99th Annual Meeting of the American Association for Cancer Research: 601–602, 12 Apr 2008. University of California, San Francisco, San Francisco, California, USA Fong L, Kwek S, Kavanagh B, et al. CTLA-4 blockade for hormone refractory prostate cancer: dose-dependent induction of CD8+ T cell activation and clinical responses. 99th Annual Meeting of the American Association for Cancer Research: 601–602, 12 Apr 2008. University of California, San Francisco, San Francisco, California, USA
35.
go back to reference Beer TM, Slovin SF, Higano CS, et al. Prostate Cancer Clinical Trials Consortium. Phase I trial of ipilimumab alone and in combination with radiotherapy in patients with metastatic castration resistant prostate cancer. 44th Annual Meeting of the American Society of Clinical Oncology: abstr. 5004, 30 May 2008. Available from URL: http://www.asco.org. Medarex, Princeton, New Jersey, USA Beer TM, Slovin SF, Higano CS, et al. Prostate Cancer Clinical Trials Consortium. Phase I trial of ipilimumab alone and in combination with radiotherapy in patients with metastatic castration resistant prostate cancer. 44th Annual Meeting of the American Society of Clinical Oncology: abstr. 5004, 30 May 2008. Available from URL: http://​www.​asco.​org. Medarex, Princeton, New Jersey, USA
36.
go back to reference Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell Non-Hodgkin lymphoma. Clinical cancer research: an official journal of the American Association for Cancer Research 15: 6446–6453, No. 20, 15 Oct 2009. Mayo Clinic, Rochester, Minnesota, USACrossRef Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell Non-Hodgkin lymphoma. Clinical cancer research: an official journal of the American Association for Cancer Research 15: 6446–6453, No. 20, 15 Oct 2009. Mayo Clinic, Rochester, Minnesota, USACrossRef
37.
go back to reference Medarex Inc. Ipilimumab (MDX-010) Safety and Clinical Response Data in Lymphomas and Leukemia Presented at the 48th American Society of Hematology Annual Meeting. Media Release: 11 Dec 2006. Available from URL: http://www.medarex.com Medarex Inc. Ipilimumab (MDX-010) Safety and Clinical Response Data in Lymphomas and Leukemia Presented at the 48th American Society of Hematology Annual Meeting. Media Release: 11 Dec 2006. Available from URL: http://​www.​medarex.​com
38.
go back to reference Yang JC, Beck KE, Blansfield JA, et al.. Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010). Journal of Clinical Oncology 23 (Suppl.): 166 (plus oral presentation) abstr. 2501, No. 16, Part I, 1 Jun 2005. Medarex Inc, Bloomsbury, New Jersey, USA Yang JC, Beck KE, Blansfield JA, et al.. Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010). Journal of Clinical Oncology 23 (Suppl.): 166 (plus oral presentation) abstr. 2501, No. 16, Part I, 1 Jun 2005. Medarex Inc, Bloomsbury, New Jersey, USA
39.
go back to reference Hodi FS, Seiden M, Butler M, et al. Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody blockade in patients previously vaccinated with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF). 40th Annual Meeting of the American Society of Clinical Oncology: 172, Jun 2004. Medarex, Bloomsbury, NJ, USA Hodi FS, Seiden M, Butler M, et al. Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody blockade in patients previously vaccinated with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF). 40th Annual Meeting of the American Society of Clinical Oncology: 172, Jun 2004. Medarex, Bloomsbury, NJ, USA
40.
go back to reference Weber JS, Berman D, Siegel J, et al. Clinical activity of ipilimumab in patients with advanced melanoma and brain metastases. 33rd Congress of the European Society for Medical Oncology: abstr. 786P, 12 Sep 2008. Available from URL: http://annonc.oxfordjournals.org. Bristol-Myers-Squibb, Wallingford, Connecticut, USA Weber JS, Berman D, Siegel J, et al. Clinical activity of ipilimumab in patients with advanced melanoma and brain metastases. 33rd Congress of the European Society for Medical Oncology: abstr. 786P, 12 Sep 2008. Available from URL: http://​annonc.​oxfordjournals.​org. Bristol-Myers-Squibb, Wallingford, Connecticut, USA
41.
go back to reference Lebbe C, Hoos A, Chin K, et al. Effect of dose on efficacy and safety in ipilimumab-treated patients with advanced melanoma — results from a phase II, randomized, dose-ranging study. 33rd Congress of the European Society for Medical Oncology: abstr. 769O, 12 Sep 2008. Available from URL: http://annonc.oxfordjournals.org. Saint-Louis Hospital, Paris, France Lebbe C, Hoos A, Chin K, et al. Effect of dose on efficacy and safety in ipilimumab-treated patients with advanced melanoma — results from a phase II, randomized, dose-ranging study. 33rd Congress of the European Society for Medical Oncology: abstr. 769O, 12 Sep 2008. Available from URL: http://​annonc.​oxfordjournals.​org. Saint-Louis Hospital, Paris, France
42.
go back to reference Cell Genesys Inc, Medarex Inc. Cell Genesys and Medarex Announce Encouraging Interim Results from a Phase 1 Combination Therapy Trial With GVAX(R) Immuno-therapy for Prostate Cancer and Ipilimumab (MDX-010) Antibody. Media Release: 3 Jun 2006. Available from URL: http://www.cellgenesys.com Cell Genesys Inc, Medarex Inc. Cell Genesys and Medarex Announce Encouraging Interim Results from a Phase 1 Combination Therapy Trial With GVAX(R) Immuno-therapy for Prostate Cancer and Ipilimumab (MDX-010) Antibody. Media Release: 3 Jun 2006. Available from URL: http://​www.​cellgenesys.​com
43.
go back to reference Bristol-Myers Squibb Company. Phase III Study of Investigational Compound Ipilimumab Achieves Primary Endpoint of Improvement in Overall Survival in Previously-Untreated Patients with Metastatic Melanoma. Media Release: 22 Mar 2011. Available from URL: http://www.bms.com Bristol-Myers Squibb Company. Phase III Study of Investigational Compound Ipilimumab Achieves Primary Endpoint of Improvement in Overall Survival in Previously-Untreated Patients with Metastatic Melanoma. Media Release: 22 Mar 2011. Available from URL: http://​www.​bms.​com
44.
go back to reference Medarex Inc. Medarex Highlights Oncology Pipeline at Needham Cancer Therapeutics Conference in New York City. Media Release: 26 Mar 2009. Available from URL: http://www.medarex.com Medarex Inc. Medarex Highlights Oncology Pipeline at Needham Cancer Therapeutics Conference in New York City. Media Release: 26 Mar 2009. Available from URL: http://​www.​medarex.​com
46.
go back to reference Medarex Inc. Medarex Announces Special Protocol Assessment Agreement With the FDA to Initiate Registrational Trial for Ipilimumab (MDX-010) Combination With Chemotherapy in First-Line Metastatic Melanoma Patients. Media Release: 19 Jun 2006. Available from URL: http://www.medarex.com Medarex Inc. Medarex Announces Special Protocol Assessment Agreement With the FDA to Initiate Registrational Trial for Ipilimumab (MDX-010) Combination With Chemotherapy in First-Line Metastatic Melanoma Patients. Media Release: 19 Jun 2006. Available from URL: http://​www.​medarex.​com
47.
go back to reference Medarex Inc. Medarex Announces FDA Fast Track Designations for Ipilimumab for the Treatment of Metastatic Melanoma; Fast Track Designations for First-Line Use in Combination With Chemotherapy and Second-Line Use as Monotherapy. Media Release: 7 Dec 2006. Available from URL: http://www.medarex.com Medarex Inc. Medarex Announces FDA Fast Track Designations for Ipilimumab for the Treatment of Metastatic Melanoma; Fast Track Designations for First-Line Use in Combination With Chemotherapy and Second-Line Use as Monotherapy. Media Release: 7 Dec 2006. Available from URL: http://​www.​medarex.​com
Metadata
Title
Ipilimumab
First Global Approval
Authors
Fiona Cameron
Glenn Whiteside
Caroline Perry
Publication date
01-05-2011
Publisher
Springer International Publishing
Published in
Drugs / Issue 8/2011
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/11594010-000000000-00000

Other articles of this Issue 8/2011

Drugs 8/2011 Go to the issue

Adis Drug Evaluation

Tesamorelin

Adis Drug Profile

Denosumab